AssetMark Inc
AERI

AssetMark Inc’s Aerie Pharmaceuticals AERI Stock Holding History

AssetMark Inc’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-7
Closed – – 1459
2015
Q4 		$0 Buy
7
+5
+250% +$117 ﹤0.01% 1505
2015
Q3 		$0 Buy
+2
New +$36 ﹤0.01% 879

Other funds holding AERI

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AssetMark Inc's AERI Position: Q1 2016 in Review

AssetMark Inc sold out of Aerie Pharmaceuticals (AERI) in Q1 2016, closing a stake of 7 shares.

AssetMark Inc first reported a position in AERI in Q3 2015 and held it in 2 quarters. The position peaked at $0 in Q4 2015. 102 funds tracked by Wall St. Rank hold AERI as of Q1 2016.

  • AssetMark Inc reported no remaining Aerie Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • AssetMark Inc sold 7 Aerie Pharmaceuticals shares in Q1 2016.
  • AssetMark Inc first reported a position in Aerie Pharmaceuticals in Q3 2015 and held it in 2 quarters.
  • AssetMark Inc's Aerie Pharmaceuticals position peaked at $0 in Q4 2015.
  • 102 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2016.

Based on AssetMark Inc's 13F filing for Q1 2016, filed 13 May 2016.